The ophthalmic injectable market size is projected to be worth USD 18.8 Billion in 2023. The market is likely to surpass USD 30.2 Billion by 2033 at a CAGR of 4.9% during the forecast period. The increasing frequency of aberrant blood vessel growth or blood vessel hemorrhage in an effort to support market expansion.
Numerous retinal disorders, such as wet age-related macular degeneration (AMD) and diabetic retinopathy, are linked to abnormal blood vessels. Repeated injections are frequently necessary, particularly for long-lasting diseases like AMD and diabetic retinopathy. So promoting market expansion.
The worldwide ophthalmic injectables market is being driven by an increase in the prevalence of eye ailments and diseases. The increased prevalence of eye disorders such as glaucoma, cataracts, macular degeneration, and diabetic retinopathy has resulted in a greater demand for effective ophthalmic injectables to control and treat these conditions.
Other Drivers Propelling the Demand for Ophthalmic Injectable include:
Challenges for Companies /Manufacturers in the Ophthalmic Injectable Market:
Opportunities in the Ophthalmic Injectable Industry:
Latest Trends in the Ophthalmic Injectable Market:
| Attributes | Details |
|---|---|
| Ophthalmic Injectable Market Size (2023) | USD 18.8 Billion |
| Ophthalmic Injectable Market Projected Size (2033) | USD 30.2 Billion |
| Value CAGR (2023 to 2033) | 4.9% |
From 2017 to 2022, the global ophthalmic injectable market experienced a CAGR of 4.8%, reaching a market size of USD 18.8 billion in 2023.
From 2017 to 2022, the global ophthalmic injectable industry witnessed steady growth due to the shift towards minimally invasive treatments. The landscape of treatment for numerous eye disorders has been completely transformed by the development of novel ocular injectables such anti-vascular endothelial growth factor (anti-VEGF) medicines and corticosteroids. These innovations have improved treatment outcomes and patient satisfaction, leading to increasing usage and market development.
In ophthalmology, there has been a paradigm shift towards minimally invasive treatments. Ophthalmic injectables provide targeted and localized drug delivery to the eye, making them a less invasive alternative to surgical interventions. The inclination for minimally invasive procedures has contributed to the increased demand for ophthalmic injectables.
Future Forecast for Ophthalmic Injectable Industry:
Looking ahead, the global ophthalmic injectable industry is expected to rise at a CAGR of 4.9% from 2023 to 2033. During the forecast period, the market size is expected to reach USD 30.2 billion in 2033.
Future developments in drug delivery methods offer hope for ophthalmic injectables. The duration and effectiveness of treatment can be increased with the development of sustained-release implants, micro/nano-particles, and intelligent delivery systems. These developments might result in the release of novel injectables with improved therapeutic profiles, spurring market expansion.
Personalised medicine is the way of the future of healthcare, and ophthalmology is no exception. The creation of personalised ophthalmic injectables catered to the needs of specific individuals may be facilitated by improvements in genetic screening and biomarker identification. This individualized strategy may improve treatment results and spur market expansion.
| Country | The United States |
|---|---|
| Market Size (USD billion) by End of Forecast Period (2033) | USD 11.9 billion |
| CAGR % 2023 to End of Forecast (2033) | 4.7% |
The ophthalmic injectable industry in the United States is expected to reach a market value of USD 11.9 billion by 2033, expanding at a CAGR of 4.7%. The ophthalmic injectable market in the United States is expected to grow as the country's mental health awareness grows. Age-related macular degeneration is becoming more and more prevalent across the nation.
Age-related macular degeneration (AMD) affected 19.8 million (12.6%) Americans aged 40 and over in 2019, according to the Centers for Disease Control and Prevention. It's probable that injectable therapies for macular degeneration will be even more successful and require less frequent administration. Thus, the market is growing as ophthalmic injectables are being used for therapeutic purposes.
| Country | The United Kingdom |
|---|---|
| Market Size (USD billion) by End of Forecast Period (2033) | USD 800.0 million |
| CAGR % 2023 to End of Forecast (2033) | 4.4% |
The ophthalmic injectable industry in the United Kingdom is expected to reach a market value of USD 800.0 million by 2033, expanding at a CAGR of 4.4% during the forecast period. The market in the United Kingdom is expected to grow due to the increased preference for minimally invasive treatment options of eye diseases.
Compared to conventional surgical treatments, ophthalmic injectables are frequently thought of as being minimally invasive. Due to their convenience, shorter recovery times, and decreased risk of problems, these non-surgical therapy methods are preferred by many patients. The rising demand for ophthalmic injectables has been influenced by this tendency for least invasive procedures.
| Country | China |
|---|---|
| Market Size (USD billion) by End of Forecast Period (2033) | USD 1.7 billion |
| CAGR % 2023 to End of Forecast (2033) | 5.4% |
The ophthalmic injectable industry in China is anticipated to reach a market value of USD 1.7 billion by 2033, moving at a CAGR of 5.4% during the forecast period. The ophthalmic injectable industry in China is expected to grow prominently due to the prevalence of diabetic retinopathy.
A main factor in diabetes vision loss and blindness is diabetic retinopathy (DR). Injectable treatments for diabetic retinopathy are likely to be considerably more effective and demand less frequent administration. As a result of the increased usage of ophthalmic injectables for therapeutic purposes, the market is expanding.
| Country | Japan |
|---|---|
| Market Size (USD billion) by End of Forecast Period (2033) | USD 755.0 million |
| CAGR % 2023 to End of Forecast (2033) | 4.2% |
The ophthalmic injectable industry in Japan is estimated to reach a market value of USD 755.0 million by 2033, thriving at a CAGR of 10.9%. Due to the development in the ophthalmic healthcare, the Japanese market is expected to increase. In Japan, the regulatory landscape for digital therapies is changing.
Significant progress has been made in ophthalmic injectables and associated technologies. Newer medications with higher efficacy and safety characteristics have been released, appealing patients as well as healthcare professionals. The availability of new therapeutic alternatives has boosted demand for these injectables.
| Country | South Korea |
|---|---|
| Market Size (USD billion) by End of Forecast Period (2033) | USD 395.0 million |
| CAGR % 2023 to End of Forecast (2033) | 4.1% |
The ophthalmic injectable industry in South Korea is expected to reach a market value of USD 395.0 million by 2033, expanding at a CAGR of 4.1% during the forecast period. The market in South Korea is expected to develop as people become more aware of the importance of mental health.
The general public is becoming more aware of eye health and the significance of frequent eye exams. Improved diagnostic equipment and procedures enable earlier diagnosis of eye problems, increasing demand for ophthalmic injectables as a therapy option.
The anti-VEGF dominated the ophthalmic injectable industry with a market of 37.6% in 2022. This segment captures a significant market share in 2023 due to its ease of use.
A patient may benefit from in-person psychotherapy sessions enhanced with digital tools or platforms in a combination therapy approach. This could involve using smartphone apps for self-monitoring and self-help tools, joining online support groups, or participating in virtual reality-based exposure therapy.
Macular degeneration dominated the ophthalmic injectable industry with a share of 31.8% in 2022. Due to the rising prevalence of macular degeneration. Macular degeneration is becoming more common over the world, which is causing the market to expand.
WHO estimates that there were about 8 million cases of age-related macular degeneration in 2022. For improved therapeutic results, injectable medications are used in the majority of macular degeneration therapies.
The hospital pharmacies dominated the ophthalmic injectable industry with a share of 31.8% in 2022. This segment captures a significant market share in 2023 due to the demand for accessible and convenience.
Hospital pharmacy may contribute significantly to the patient care team by reviewing medications and educating patients about various eye conditions in clinic settings. As a result, hospital pharmacists are essential to eye treatment.
The ophthalmic injectable industry is highly competitive. Numerous players are looking out to hold on to market share globally. Key players are thus, trying to adopt new and effective strategies to stay ahead of the competition.
Key Strategies Adopted by the Players
Companies make significant investments in research and development to bring new goods to market that offer improved efficiency, dependability, and cost-effectiveness. Companies may set themselves apart from rivals and adapt to clients' changing requirements thanks to product innovation.
Strategic partnerships and collaborations between leading organisations in the sector are frequently formed to take advantage of one another's advantages and broaden their market reach. These partnerships can provide businesses access to emerging markets and technology.
The market for ophthalmic injectables is expanding significantly in developing nations like China and India. Important firms are creating local production facilities and bolstering their distribution networks in an effort to increase their market share.
In order to strengthen their market positions, increase the scope of their product offerings, and gain access to new markets, major companies in the ophthalmic injectable market frequently participate in mergers and acquisitions.
Key Developments in the Ophthalmic Injectable Market:
Table 01: Global Market Value (US$ Million) Analysis, By Drug Class, 2017 to 2033
Table 02: Global Market Value (US$ Million) Analysis, By Indication, 2017 to 2033
Table 03: Global Market Value (US$ Million) Analysis, By Distribution Channel, 2017 to 2033
Table 04: Global Market Value (US$ Million) Analysis, By Region, 2017 to 2033
Table 05: North America Historical Market Value (US$ Million) Analysis, By Country, 2017 to 2033
Table 06: North America Market Value (US$ Million) Analysis, By Drug Class, 2017 to 2033
Table 07: North America Market Value (US$ Million) Analysis, By Indication, 2017 to 2033
Table 08: North America Market Value (US$ Million) Analysis, By Distribution Channel, 2017 to 2033
Table 09: Latin America Historical Market Value (US$ Million) Analysis, By Country, 2017 to 2033
Table 10: Latin America Market Value (US$ Million) Analysis, By Drug Class, 2017 to 2033
Table 11: Latin America Market Value (US$ Million) Analysis, By Indication, 2017 to 2033
Table 12: Latin America Market Value (US$ Million) Analysis, By Distribution Channel, 2017 to 2033
Table 13: Europe Historical Market Value (US$ Million) Analysis, By Country, 2017 to 2033
Table 14: Europe Market Value (US$ Million) Analysis, By Drug Class, 2017 to 2033
Table 15: Europe Market Value (US$ Million) Analysis, By Indication, 2017 to 2033
Table 16: Europe Market Value (US$ Million) Analysis, By Distribution Channel, 2017 to 2033
Table 17: East Asia Historical Market Value (US$ Million) Analysis, By Country, 2017 to 2033
Table 18: East Asia Market Value (US$ Million) Analysis, By Drug Class, 2017 to 2033
Table 19: East Asia Market Value (US$ Million) Analysis, By Indication, 2017 to 2033
Table 20: East Asia Market Value (US$ Million) Analysis, By Distribution Channel, 2017 to 2033
Table 21: South Asia Historical Market Value (US$ Million) Analysis, By Country, 2017 to 2033
Table 22: South Asia Market Value (US$ Million) Analysis, By Drug Class, 2017 to 2033
Table 23: South Asia Market Value (US$ Million) Analysis, By Indication, 2017 to 2033
Table 24: South Asia Market Value (US$ Million) Analysis, By Distribution Channel, 2017 to 2033
Table 25: Oceania Historical Market Value (US$ Million) Analysis, By Country, 2017 to 2033
Table 26: Oceania Market Value (US$ Million) Analysis, By Drug Class, 2017 to 2033
Table 27: Oceania Market Value (US$ Million) Analysis, By Indication, 2017 to 2033
Table 28: Oceania Market Value (US$ Million) Analysis, By Distribution Channel, 2017 to 2033
Table 29: Middle East and Africa Historical Market Value (US$ Million) Analysis, By Country, 2017 to 2033
Table 30: Middle East and Africa Market Value (US$ Million) Analysis, By Drug Class, 2017 to 2033
Table 31: Middle East and Africa Market Value (US$ Million) Analysis, By Indication, 2017 to 2033
Table 32: Middle East and Africa Market Value (US$ Million) Analysis, By Distribution Channel, 2017 to 2033
Figure 01: Global Historical Market Value (US$ Million) Analysis, 2017 to 2022
Figure 02: Global Current and Future Market Value (US$ Million), 2023 to 2033 & Y-o-Y Growth Trend Analysis, 2023 to 2033
Figure 03: Global Market Absolute $ Opportunity, 2023 to 2033
Figure 04: Global Market Share Analysis (%), By Drug Class, 2022 & 2033
Figure 05: Global Market Y-o-Y Analysis (%), By Drug Class, 2023 to 2033
Figure 06: Market Attractiveness Analysis By Drug Class, 2023 to 2033
Figure 07: Global Market Share Analysis (%), By Indication, 2022 & 2033
Figure 08: Global Market Y-o-Y Analysis (%), By Indication, 2023 to 2033
Figure 09: Market Attractiveness Analysis By Indication, 2023 to 2033
Figure 10: Global Market Share Analysis (%), By Distribution Channel, 2022 & 2033
Figure 11: Global Market Y-o-Y Analysis (%), By Distribution Channel, 2023 to 2033
Figure 12: Market Attractiveness Analysis By Distribution Channel, 2023 to 2033
Figure 13: Global Market Share Analysis (%), By Region, 2022 & 2033
Figure 14: Global Market Y-o-Y Analysis (%), By Region, 2023 to 2033
Figure 15: Market Attractiveness Analysis By Region, 2023 to 2033
Figure 16: North America Market Share Analysis (%), By Drug Class, 2023 (E)
Figure 17: North America Market Share Analysis (%), By Indication, 2023 (E)
Figure 18: North America Market Share Analysis (%), By Distribution Channel, 2023 (E)
Figure 19: North America Market Share Analysis (%), By Country, 2023 (E)
Figure 20: North America Historical Market Value (US$ Million) Analysis, 2017 to 2022
Figure 21: North America Current and Future Market Value (US$ Million), 2023 to 2033 & Y-o-Y Growth Trend Analysis, 2023 to 2033
Figure 22: North America Market Share Analysis (%), By Drug Class, 2023 (E)
Figure 23: North America Market Share Analysis (%), By Indication, 2023 (E)
Figure 24: North America Market Share Analysis (%), By Distribution Channel, 2023 (E)
Figure 25: North America Market Share Analysis (%), By Country, 2023 (E)
Figure 26: USA Market Value Proportion Analysis, 2022
Figure 27: Global Vs USA Y-o-Y Growth Comparison, 2023 to 2033
Figure 28: USA Market Share Analysis (%) By Drug Class, 2022 & 2033
Figure 29: USA Market Share Analysis (%) By Indication, 2022 & 2033
Figure 30: USA Market Share Analysis (%) By Distribution Channel, 2022 & 2033
Figure 31: Canada Market Value Proportion Analysis, 2022
Figure 32: Global Vs Canada Y-o-Y Growth Comparison, 2023 to 2033
Figure 33: Canada Market Share Analysis (%) By Drug Class, 2022 & 2033
Figure 34: Canada Market Share Analysis (%) By Indication, 2022 & 2033
Figure 35: Canada Market Share Analysis (%) By Distribution Channel, 2022 & 2033
Figure 36: Latin America Market Share Analysis (%), By Drug Class, 2023 (E)
Figure 37: Latin America Market Share Analysis (%), By Indication, 2023 (E)
Figure 38: Latin America Market Share Analysis (%), By Distribution Channel, 2023 (E)
Figure 39: Latin America Market Share Analysis (%), By Country, 2023 (E)
Figure 40: Latin America Historical Market Value (US$ Million) Analysis, 2017 to 2022
Figure 41: Latin America Current and Future Market Value (US$ Million), 2023 to 2033 & Y-o-Y Growth Trend Analysis, 2023 to 2033
Figure 42: Latin America Market Share Analysis (%), By Drug Class, 2023 (E)
Figure 43: Latin America Market Share Analysis (%), By Indication, 2023 (E)
Figure 44: Latin America Market Share Analysis (%), By Distribution Channel, 2023 (E)
Figure 45: Latin America Market Share Analysis (%), By Country, 2023 (E)
Figure 46: Brazil Market Value Proportion Analysis, 2022
Figure 47: Global Vs Brazil Y-o-Y Growth Comparison, 2023 to 2033
Figure 48: Brazil Market Share Analysis (%) By Drug Class, 2022 & 2033
Figure 49: Brazil Market Share Analysis (%) By Indication, 2022 & 2033
Figure 50: Brazil Market Share Analysis (%) By Distribution Channel, 2022 & 2033
Figure 51: Mexico Market Value Proportion Analysis, 2022
Figure 52: Global Vs Mexico Y-o-Y Growth Comparison, 2023 to 2033
Figure 53: Mexico Market Share Analysis (%) By Drug Class, 2022 & 2033
Figure 54: Mexico Market Share Analysis (%) By Indication, 2022 & 2033
Figure 55: Mexico Market Share Analysis (%) By Distribution Channel, 2022 & 2033
Figure 56: Argentina Market Value Proportion Analysis, 2022
Figure 57: Global Vs Argentina Y-o-Y Growth Comparison, 2023 to 2033
Figure 58: Argentina Market Share Analysis (%) By Drug Class, 2022 & 2033
Figure 59: Argentina Market Share Analysis (%) By Indication, 2022 & 2033
Figure 60: Argentina Market Share Analysis (%) By Distribution Channel, 2022 & 2033
Figure 61: Europe Market Share Analysis (%), By Drug Class, 2023 (E)
Figure 62: Europe Market Share Analysis (%), By Indication, 2023 (E)
Figure 63: Europe Market Share Analysis (%), By Distribution Channel, 2023 (E)
Figure 64: Europe Market Share Analysis (%), By Country, 2023 (E)
Figure 65: Europe Historical Market Value (US$ Million) Analysis, 2017 to 2022
Figure 66: Europe Current and Future Market Value (US$ Million), 2023 to 2033 & Y-o-Y Growth Trend Analysis, 2023 to 2033
Figure 67: Europe Market Share Analysis (%), By Drug Class, 2023 (E)
Figure 68: Europe Market Share Analysis (%), By Indication, 2023 (E)
Figure 69: Europe Market Share Analysis (%), By Distribution Channel, 2023 (E)
Figure 70: Europe Market Share Analysis (%), By Country, 2023 (E)
Figure 71: UK Market Value Proportion Analysis, 2022
Figure 72: Global Vs UK Y-o-Y Growth Comparison, 2023 to 2033
Figure 73: UK Market Share Analysis (%) By Drug Class, 2022 & 2033
Figure 74: UK Market Share Analysis (%) By Indication, 2022 & 2033
Figure 75: UK Market Share Analysis (%) By Distribution Channel, 2022 & 2033
Figure 76: Germany Market Value Proportion Analysis, 2022
Figure 77: Global Vs Germany Y-o-Y Growth Comparison, 2023 to 2033
Figure 78: Germany Market Share Analysis (%) By Drug Class, 2022 & 2033
Figure 79: Germany Market Share Analysis (%) By Indication, 2022 & 2033
Figure 80: Germany Market Share Analysis (%) By Distribution Channel, 2022 & 2033
Figure 81: France Market Value Proportion Analysis, 2022
Figure 82: Global Vs France Y-o-Y Growth Comparison, 2023 to 2033
Figure 83: France Market Share Analysis (%) By Drug Class, 2022 & 2033
Figure 84: France Market Share Analysis (%) By Indication, 2022 & 2033
Figure 85: France Market Share Analysis (%) By Distribution Channel, 2022 & 2033
Figure 86: Italy Market Value Proportion Analysis, 2022
Figure 87: Global Vs Italy Y-o-Y Growth Comparison, 2023 to 2033
Figure 88: Italy Market Share Analysis (%) By Drug Class, 2022 & 2033
Figure 89: Italy Market Share Analysis (%) By Indication, 2022 & 2033
Figure 90: Italy Market Share Analysis (%) By Distribution Channel, 2022 & 2033
Figure 91: Spain Market Value Proportion Analysis, 2022
Figure 92: Global Vs Spain Y-o-Y Growth Comparison, 2023 to 2033
Figure 93: Spain Market Share Analysis (%) By Drug Class, 2022 & 2033
Figure 94: Spain Market Share Analysis (%) By Indication, 2022 & 2033
Figure 95: Spain Market Share Analysis (%) By Distribution Channel, 2022 & 2033
Figure 96: Benelux Market Value Proportion Analysis, 2022
Figure 97: Global Vs Benelux Y-o-Y Growth Comparison, 2023 to 2033
Figure 98: Benelux Market Share Analysis (%) By Drug Class, 2022 & 2033
Figure 99: Benelux Market Share Analysis (%) By Indication, 2022 & 2033
Figure 100: Benelux Market Share Analysis (%) By Distribution Channel, 2022 & 2033
Figure 101: Russia Market Value Proportion Analysis, 2022
Figure 102: Global Vs Russia Y-o-Y Growth Comparison, 2023 to 2033
Figure 103: Russia Market Share Analysis (%) By Drug Class, 2022 & 2033
Figure 104: Russia Market Share Analysis (%) By Indication, 2022 & 2033
Figure 105: Russia Market Share Analysis (%) By Distribution Channel, 2022 & 2033
Figure 106: East Asia Market Share Analysis (%), By Drug Class, 2023 (E)
Figure 107: East Asia Market Share Analysis (%), By Indication, 2023 (E)
Figure 108: East Asia Market Share Analysis (%), By Distribution Channel, 2023 (E)
Figure 109: East Asia Market Share Analysis (%), By Country, 2023 (E)
Figure 110: East Asia Historical Market Value (US$ Million) Analysis, 2017 to 2022
Figure 111: East Asia Current and Future Market Value (US$ Million), 2023 to 2033 & Y-o-Y Growth Trend Analysis, 2023 to 2033
Figure 112: East Asia Market Share Analysis (%), By Drug Class, 2023 (E)
Figure 113: East Asia Market Share Analysis (%), By Indication, 2023 (E)
Figure 114: East Asia Market Share Analysis (%), By Distribution Channel, 2023 (E)
Figure 115: East Asia Market Share Analysis (%), By Country, 2023 (E)
Figure 116: China Market Value Proportion Analysis, 2022
Figure 117: Global Vs China Y-o-Y Growth Comparison, 2023 to 2033
Figure 118: China Market Share Analysis (%) By Drug Class, 2022 & 2033
Figure 119: China Market Share Analysis (%) By Indication, 2022 & 2033
Figure 120: China Market Share Analysis (%) By Distribution Channel, 2022 & 2033
Figure 121: Japan Market Value Proportion Analysis, 2022
Figure 122: Global Vs Japan Y-o-Y Growth Comparison, 2023 to 2033
Figure 123: Japan Market Share Analysis (%) By Drug Class, 2022 & 2033
Figure 124: Japan Market Share Analysis (%) By Indication, 2022 & 2033
Figure 125: Japan Market Share Analysis (%) By Distribution Channel, 2022 & 2033
Figure 126: South Korea Market Value Proportion Analysis, 2022
Figure 127: Global Vs South Korea Y-o-Y Growth Comparison, 2023 to 2033
Figure 128: South Korea Market Share Analysis (%) By Drug Class, 2022 & 2033
Figure 129: South Korea Market Share Analysis (%) By Indication, 2022 & 2033
Figure 130: South Korea Market Share Analysis (%) By Distribution Channel, 2022 & 2033
Figure 131: South Asia Market Share Analysis (%), By Drug Class, 2023 (E)
Figure 132: South Asia Market Share Analysis (%), By Indication, 2023 (E)
Figure 133: South Asia Market Share Analysis (%), By Distribution Channel, 2023 (E)
Figure 134: South Asia Market Share Analysis (%), By Country, 2023 (E)
Figure 135: South Asia Historical Market Value (US$ Million) Analysis, 2017 to 2022
Figure 136: South Asia Current and Future Market Value (US$ Million), 2023 to 2033 & Y-o-Y Growth Trend Analysis, 2023 to 2033
Figure 137: South Asia Market Share Analysis (%), By Drug Class, 2023 (E)
Figure 138: South Asia Market Share Analysis (%), By Indication, 2023 (E)
Figure 139: South Asia Market Share Analysis (%), By Distribution Channel, 2023 (E)
Figure 140: South Asia Market Share Analysis (%), By Country, 2023 (E)
Figure 141: India Market Value Proportion Analysis, 2022
Figure 142: Global Vs India Y-o-Y Growth Comparison, 2023 to 2033
Figure 143: India Market Share Analysis (%) By Drug Class, 2022 & 2033
Figure 144: India Market Share Analysis (%) By Indication, 2022 & 2033
Figure 145: India Market Share Analysis (%) By Distribution Channel, 2022 & 2033
Figure 146: Malaysia Market Value Proportion Analysis, 2022
Figure 147: Global Vs Malaysia Y-o-Y Growth Comparison, 2023 to 2033
Figure 148: Malaysia Market Share Analysis (%) By Drug Class, 2022 & 2033
Figure 149: Malaysia Market Share Analysis (%) By Indication, 2022 & 2033
Figure 150: Malaysia Market Share Analysis (%) By Distribution Channel, 2022 & 2033
Figure 151: Thailand Market Value Proportion Analysis, 2022
Figure 152: Global Vs Thailand Y-o-Y Growth Comparison, 2023 to 2033
Figure 153: Thailand Market Share Analysis (%) By Drug Class, 2022 & 2033
Figure 154: Thailand Market Share Analysis (%) By Indication, 2022 & 2033
Figure 155: Thailand Market Share Analysis (%) By Distribution Channel, 2022 & 2033
Figure 156: Indonesia Market Value Proportion Analysis, 2022
Figure 157: Global Vs Indonesia Y-o-Y Growth Comparison, 2023 to 2033
Figure 158: Indonesia Market Share Analysis (%) By Drug Class, 2022 & 2033
Figure 159: Indonesia Market Share Analysis (%) By Indication, 2022 & 2033
Figure 160: Indonesia Market Share Analysis (%) By Distribution Channel, 2022 & 2033
Figure 161: Oceania Market Share Analysis (%), By Drug Class, 2023 (E)
Figure 162: Oceania Market Share Analysis (%), By Indication, 2023 (E)
Figure 163: Oceania Market Share Analysis (%), By Distribution Channel, 2023 (E)
Figure 164: Oceania Market Share Analysis (%), By Country, 2023 (E)
Figure 165: Oceania Historical Market Value (US$ Million) Analysis, 2017 to 2022
Figure 166: Oceania Current and Future Market Value (US$ Million), 2023 to 2033 & Y-o-Y Growth Trend Analysis, 2023 to 2033
Figure 167: Oceania Market Share Analysis (%), By Drug Class, 2023 (E)
Figure 168: Oceania Market Share Analysis (%), By Indication, 2023 (E)
Figure 169: Oceania Market Share Analysis (%), By Distribution Channel, 2023 (E)
Figure 170: Oceania Market Share Analysis (%), By Country, 2023 (E)
Figure 171: Australia Market Value Proportion Analysis, 2022
Figure 172: Global Vs Australia Y-o-Y Growth Comparison, 2023 to 2033
Figure 173: Australia Market Share Analysis (%) By Drug Class, 2022 & 2033
Figure 174: Australia Market Share Analysis (%) By Indication, 2022 & 2033
Figure 175: Australia Market Share Analysis (%) By Distribution Channel, 2022 & 2033
Figure 176: New Zealand Market Value Proportion Analysis, 2022
Figure 177: Global Vs New Zealand Y-o-Y Growth Comparison, 2023 to 2033
Figure 178: New Zealand Market Share Analysis (%) By Drug Class, 2022 & 2033
Figure 179: New Zealand Market Share Analysis (%) By Indication, 2022 & 2033
Figure 180: New Zealand Market Share Analysis (%) By Distribution Channel, 2022 & 2033
Figure 181: Middle East and Africa Market Share Analysis (%), By Drug Class, 2023 (E)
Figure 182: Middle East and Africa Market Share Analysis (%), By Indication, 2023 (E)
Figure 183: Middle East and Africa Market Share Analysis (%), By Distribution Channel, 2023 (E)
Figure 184: Middle East and Africa Market Share Analysis (%), By Country, 2023 (E)
Figure 185: Middle East and Africa Historical Market Value (US$ Million) Analysis, 2017 to 2022
Figure 186: Middle East and Africa Current and Future Market Value (US$ Million), 2023 to 2033 & Y-o-Y Growth Trend Analysis, 2023 to 2033
Figure 187: Middle East and Africa Market Share Analysis (%), By Drug Class, 2023 (E)
Figure 188: Middle East and Africa Market Share Analysis (%), By Indication, 2023 (E)
Figure 189: Middle East and Africa Market Share Analysis (%), By Distribution Channel, 2023 (E)
Figure 190: Middle East and Africa Market Share Analysis (%), By Country, 2023 (E)
Figure 191: GCC Countries Market Value Proportion Analysis, 2022
Figure 192: Global Vs GCC Countries Y-o-Y Growth Comparison, 2023 to 2033
Figure 193: GCC Countries Market Share Analysis (%) By Drug Class, 2022 & 2033
Figure 194: GCC Countries Market Share Analysis (%) By Indication, 2022 & 2033
Figure 195: GCC Countries Market Share Analysis (%) By Distribution Channel, 2022 & 2033
Figure 196: Türkiye Market Value Proportion Analysis, 2022
Figure 197: Global Vs Türkiye Y-o-Y Growth Comparison, 2023 to 2033
Figure 198: Türkiye Market Share Analysis (%) By Drug Class, 2022 & 2033
Figure 199: Türkiye Market Share Analysis (%) By Indication, 2022 & 2033
Figure 200: Türkiye Market Share Analysis (%) By Distribution Channel, 2022 & 2033
Figure 201: South Africa Market Value Proportion Analysis, 2022
Figure 202: Global Vs South Africa Y-o-Y Growth Comparison, 2023 to 2033
Figure 203: South Africa Market Share Analysis (%) By Drug Class, 2022 & 2033
Figure 204: South Africa Market Share Analysis (%) By Indication, 2022 & 2033
Figure 205: South Africa Market Share Analysis (%) By Distribution Channel, 2022 & 2033
The market is slated to attain USD 18.8 billion in 2023.
The market is expected to expand at a CAGR of 4.9% through 2033.
Development of cutting-edge ophthalmic injectables is influencing the product’s sales.
The Japan market is expected to expand at a CAGR of 4.2% through 2033.
Anti-VEGF is extensively used in the market.
Explore Pharmaceuticals Insights
Ophthalmic Injectable Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
